BCL2 and B-cell chronic lymphocytic leukemia: Navitoclax is the first in-class oral BCL-2 (and BCL-XL) dual inhibitor that showed antileukemic activity in chronic lymphocytic leukemia (CLL), however, its further development has been limited by its target specific (BCL-XL) dose-limiting severe thrombocytopenia (22).